Fig. 3 | Scientific Reports

Fig. 3

From: Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda

Fig. 3

Dynamics of biomarker candidates for monitoring MVD progression. (a) The principal component analysis (PCA) depicts the clusters of early recovered patients (< 5 days), middle (5–10 days) and late (> 10 days) recovered patients. (b) A PCA analysis correlated and clustered all investigated biomarkers. (c–g) Biomarker candidates AST, ALT, creatinine, platelets and lymphocytes were compared between the defined phases of recovery (day of recovery) and MVD patients (day of admission). Kruskal–Wallis test was used to compute stastical differences. p-values were calculated. Significant differences are indicated as: **** < 0.0001,*** < 0.001, ** < 0.01, and * < 0.05.

Back to article page